Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00881218 · ClinicalTrials.gov registry record · Early Phase 1
Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
A Early Phase 1 study of Ischemic Heart Disease, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00881218 is a Early Phase 1 study of Ischemic Heart Disease that has completed, run by Washington University School of Medicine. The registered enrollment target is 50 participants, below the 263-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00881218, a Early Phase 1 study of Ischemic Heart Disease, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce coronary vasodilatation and demonstrate myocardial ischemia during first-pass perfusion cardiac MRI.
Conditions Studied
Interventions
- DRUG Regadenoson
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-12 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00881218
The ClinicalTrials.gov registry entry for NCT00881218 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 263-participant average among 14 other Ischemic Heart Disease trials with a reported enrollment target (81% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ischemic Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Regadenoson is the first listed.
NCT00881218 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT00881218 about?
NCT00881218 is a clinical study titled "Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson". This is a pilot study to determine whether the drug regadenoson can be used during magnetic resonance imaging to assess regions of poor blood flow to the heart. The hypothesis of this study is that a single injection of regadenoson could be used instead of a standard adenosine infusion to produce c...
What is the current status of trial NCT00881218?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 50 participants. The study started on 2009-06. Estimated completion is 2011-12.
What conditions does trial NCT00881218 study?
This clinical trial studies the following conditions: Ischemic Heart Disease.
What interventions are being tested in trial NCT00881218?
The interventions under investigation include: Regadenoson (DRUG).
Who is sponsoring clinical trial NCT00881218?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00881218 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ischemic Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor
RECRUITING
-
Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)
RECRUITING
-
Pulsed Field Ablation for Post-Infarction Ventricular Tachycardia
RECRUITING · NA
-
Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy
RECRUITING · Phase 2
-
Use of GeriKit to Better Phenotype Older Adults With Ischemic Heart Disease
RECRUITING · NA
-
Development of CIRC Technologies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.